Interferon-Induced Surface Alterations in Hairy Cells. A Review by Gamliel, Haim et al.
Scanning Microscopy 
Volume 2 Number 1 Article 46 
10-26-1987 
Interferon-Induced Surface Alterations in Hairy Cells. A Review 
Haim Gamliel 
University of Chicago Medical Center 
Dorit Gurfel 
University of Chicago Medical Center and Michael Reese Medical Center 
Shi-hua Wu 
Xi'an Medical University 
Harvey M. Golomb 
University of Chicago Medical Center and Michael Reese Medical Center 
Follow this and additional works at: https://digitalcommons.usu.edu/microscopy 
 Part of the Biology Commons 
Recommended Citation 
Gamliel, Haim; Gurfel, Dorit; Wu, Shi-hua; and Golomb, Harvey M. (1987) "Interferon-Induced Surface 
Alterations in Hairy Cells. A Review," Scanning Microscopy: Vol. 2 : No. 1 , Article 46. 
Available at: https://digitalcommons.usu.edu/microscopy/vol2/iss1/46 
This Article is brought to you for free and open access by 
the Western Dairy Center at DigitalCommons@USU. It 
has been accepted for inclusion in Scanning Microscopy 
by an authorized administrator of DigitalCommons@USU. 
For more information, please contact 
digitalcommons@usu.edu. 
Scanning Microscopy, Vol. 2, No. 1, 1988 (Pages 485-492) 0891-7035/88$3.00+.00 
Scanning Microscopy International, Chicago (AMF O'Hare), IL 60666 USA 
INTERFERON-INDUCED SURFACE ALTERATIONS IN HAIRY CELLS. A REVIEW 
*Haim Gamliel, Dorit Gurfel, **Shi-hua Wu, and Harvey M. Golomb 
Joint Hematology/Oncology Section, Department of Medicine, University of 
Chicago Medical Center and Michael Reese Medical Center, Chicago, Illinois, 
**Hematology Section, Department of Medicine, Xi'an Medical University, 
Xi'an, Shaanxi, The People's Rep.lblic of China 
(Received for publication April 10, 1987, and in revised form October 26, 1987) 
Abstract 
Hairy cells (HCs), derived from the 
peripheral blood and spleen of hairy cell leukemia 
(HCL) patients, constantly displayed both ruffles 
and microvilli. HCs which were kept in culture for 
up to three days exhibited extremely polarized and 
active surfaces with elongated microvilli and 
exaggera ted "spiked" ruffles. Cells derived from 
11 cases of HCL were treated with alpha-interferon 
(IFN) in-vitro and examined by immuno - scanning 
electron microscopy (immuno-SEM). In 8 cases, up 
to one-third of the IFN-treated hairy cells 
displayed deformed surfaces with "bubbling" 
membrane and markedl y villous bud-like formations. 
Monoclonal antibodies (MoAb), used in conjunction 
with immuno-qold labeling, facilitated better 
correlation between these morphological changes 
and the immunological profiles of the cells before 
and after interferon treatment in-vitro. Immuno-
SEM analyses revealed no remarkable changes in the 
labeling of HCs with Leu-14 and Leu-MS MoAbs 
before and after IFN treatment, even in cases 
showing membrane changes. However, a significant 
icrease in the labeling intensity for HLA-DR and 
HLA-DQ was noticed in HCs from cases where IFN-
induced membrane changes were evident. A review of 
the literature on membrane changes in IFN-treated 
cells proposes that such immuno-ultrastructural 
alterations might reflect unique interferon-
induced membrane reorganization in the target 
malignant cells. 
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Introduction 
For the first twenty years following its 
discovery by Isaacs and Lindenmann [1957], 
interferon (IFN) was studied as an antiviral 
agent. Currently, the inhibition of virus 
multiplication ('antiviral effect'), the 
inhibition of cell proliferation ('antimitogenic 
effect'), and cell regulatory activities, such as 
effects on cell differentiation and immune 
functions, are the most important effects of IFN. 
On the other hand, several groups of proteins were 
found to be induced by IFN, namely, translation-
regulatory enzymes, cell surface antigens and 
intracellular proteins detected by gel 
electrophoresis [Taylor-Papadimitriou, 1980; Van 
Damme and Billiau, 1981; Vilcek et al., 1982: 
Friedman and Vogel, 1983]. Besides intracellular 
and surface proteins, IFN treatment may also 
affect the activity of genes for cytoskeletal 
proteins [Tamm et al., 1982; Wang et al., 1984; 
discussed by Revel, 1984] . The resulting changes 
in the cytoskeleton are numerous and could lead to 
abortive mitosis as well as to abnormal control of 
cell size, shape, and function. 
Human interferons were successfully harnessed 
in t he treatment of various viral diseases 
[Merigan, 1981]. Effective therapy with IFNs, 
derived from cell culture or cloning technology, 
was also reported in hairy cell leukemia (HCL), 
chronic myelocytic leukemia, IgA myelomas, renal 
cancer, skin cancers due to papillomavirus, 
melanomas, and metastatic breast cancer [Strander, 
1983; Bonnem and Spiegel, 1984]. Studies have 
shown that IFN lead to the elimination of cancer 
cells in the blood or the tissues of the treated 
patients, but the actual mechanism of its action 
is still unknown. 
HCL is characterized by pancytopenia, 
splenomegaly, and infiltration of the bone marrow 
and spleen by distinct abnormal mononuclear cells 
[Golomb et al., 1983]. Since HCL might be 
confused with other malignant lymphomas or chronic 
lymphocytic leukemia, which are treated in an 
utterly different manner, accurate diagnosis of 
HCL is important. It is preferable initially to 
advise only splenectomy, or no treatment, rather 
than radiotherapy or chemotherapy [Golomb and 
Vardiman, 1983]. However, recent clinical studies 
indicated that most HCL patients treated with 
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alpha-IFN showed a striking clinical response to 
the drug [Quesada et al., 1984]. 
Most scanning electron microscopy (SEM) 
studies on hairy cells (HCs) initially aimed to 
determine whether these cells were of lymphocytic 
or monocytic origin [references cited in Gamliel 
et al., 1985]. Generally, these SEM studies 
revealed cells displaying ruffles (monocytoid 
features) mixed with microvilli (lymphocytoid 
features), making it impossible to favor a 
lymphocytic or monocytic nature of the HC under 
the SEM. However, recent multidisciplinary studies 
have proven that HCL cells are malignant B-
lymphocytes which display some monocyte-like 
characteristics [Reiber et al., 1977; Burns and 
Lawley, 1979; Yanovich et al., 1979; Golomb et 
al., 1982; Jansen et al., 1982]. 
Based on the surface morphology of HCs from 18 
patients, Gamliel et al. [1985] identified two 
major types of hairy cells: (i) cells showing 
areas of ruffles alongside areas of clustered 
microvilli, and (ii) cells displaying microvilli 
scattered among ruffles. 
The clinical efficacy of alpha-IFN in HCL led 
us to utilize the SEM for the study of the effect 
of IFN on HCs in-vitro. In a previous paper 
[Gamliel et al., 1987], we reported for the first 
time that HCs treated with alpha-IFN in-vitro 
displayed unique alterations in their surface 
morphology. The present report extends on seven 
more HCL cases treated with IFN in-vitro, and 
reviews other studies on IFN-induced membranal 
alterations. 
Materials and Methods 
The main guidelines for including HCL cases 
in this study were: patients with the leukemic 
form of their disease, i.e., those who had 
greater than 60% abnormal cells in the 
differential c~unts and greater than 10,000 white 
blood cells/mm. These criteria were set as it is 
relatively easy to score the HCs in such cases in 
comparison to most HCL patients who are leukopenic 
with less than 10% HCs. Eleven such patients were 
selected for evaluation of cell surface features 
before and after IFN treatment. HCL was diagnosed 
by the following tests: the presence of 'hairy' 
cells in the peripheral blood (PB) and/or bone 
marrow and spleen; the existence of tartrate-
resistant acid phosphatase isoenzyme in the 
malignant cells; the demonstration by transmission 
electron microscopy (TEM) of a ribosome-lamella 
complex in some cells; the presence of 
splenomegaly and pancytopenia, and a chronic 
clinical course. 
For the isolation of PB-HCs, samples of 
venous blood were collected in sterile evacuated 
tubes (Vacutainer Systems, Rutherford, NJ) 
containing heparin as an anticoagulant, and 
layered on a Ficoll-Paque gradient (see below). 
For the isolation of spleen HCs, 2.5 centimeter 
sections of fresh spleen tissue were kept in cold 
Hank's balance::! salt solution ( HBSS) with 1% 
heparin while they were gently teased across a 
sterile fine mesh screen, producing a liquid 
homogenate. Mononuclear cells were isolated from 
the peripheral blood and/or the spleen homogenate 
by the Ficoll-Paque density gradient method. Cells 
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were removed from the mononuclear band of the 
gradient, and washed three times in HBSS or 
Dulbecco's phosphate buffered saline (DPBS). Using 
this procedure, more than 80% of the mononuclear 
splenic cells were HCs, while the number of 
monocytes never exceeded 5% in all PB and spleen 
samples. PB cells from 6 HCL patients and splenic 
cells from 5 other cases were 6treated with IFN in-vitro. Cell suspensions (10 cells), in 2.5 ml 
RPMI medium 1640 and 10% fetal calf serum, were 
incubated in tissue culture flasks, at 37°c in a 
5% CXl humidified atmosphere. After 24 h of 
incubaton, RDa2-IFN (recombinant human leukocyte interferon; Schering Corp., Bloomfield, NJ) in a 
0.9% NaCl solution was added at a concentration of 
1000 international units per 1 ml. Control 
cultures received NaCl solution without IFN, or 
IFN in the presence of neutralizing concentration 
(50 µl/1000 IU IFN) of rabbit anti-IFN reagent 
(Interferon Sciences, Inc., New Brunswick, NJ). 
Cultures were harvested on the first, second, and 
third days of incubation for viability and 
differential cell counts, and for SEM analyses. In 
some cases, usually those with high blood counts, 
cells were also harvested after 2, 4, and 6 h. 
Viable cell counts were performed using trypan 
blue dye exclusion. For routine SEM examinations, 
cells were fixed with 2% glutaraldehyde in DPBS 
for 1 h. 
The following monoclonal antibodies (Becton 
Dickinson, Mountain View, CA) were used to study 
control and treated cells: Leu-4 (specific for T 
cells), Leu-14 (for B cells), Leu-M3 (for 
monocytes/macrophages), Leu-MS (for hairy cells 
and monocytes), anti-HLA-DR ( for B---cells and 
monocytes), and anti-HLA-DQ (Leu-10; for B cells 
and monocytes ) . 
For immune-gold labeling, cells were fixed in 
0.2% glutaraldehyde for 10 min, washed with DPBS, 
and treated with 0.lM glycine for 5 min. Cells 
were then washed with DPBS, loaded on poly-L-
lysine treated glass coverslips for 1 h, and 
washed with an 'immune' buffer (DPBS containing 1% 
bovine serum albumin and 1% decomplemented human 
AB serum). Subsequently, cells were reacted with 
50 µl of diluted monoclonal antibody for 30 min, 
washed 3 times with the 'immune' buffer, and 
incubated with 50 µl of 40 nm colloidal gold 
particles tagged with goat anti-mouse MoAb 
(GAMigG+IgM-G40; Janssen Pharmaceutica, 
Piscataway, NJ). After 30 min, cells were rinsed 
with DPBS and postfixed in 2% glutaraldehyde until 
processed for SEM. 
SEM preparation of cells was carried out 
using either conventional critical point drying 
(CPD), or the newly introduced GI'GO - air drying 
(GTGO-AD) procedure which minimizes cell shrinkage 
due to improved fixation routine [Gamliel et al., 
1983; Gamliel, 1985]. Briefly, after fixation with 
glutaraldehyde, coverslips with a monolayer of 
attached cells were either processed immediately 
for CPD [Gamliel, 1985], or incubated in DPBS 
containing 2% tannic acid and 2% guanidine-HCl, 
for 1 h, as part of the GI'GO-AD procedure. 
Thereafter, cells were thoroughly washed for 15 
min with DPBS and subsequently immersed in DPBS 
containing 2% osmium tetroxide for another hour. 
Dehydration was carried out through a graded 
series of ethanol in distilled water (25%, 50%, 
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Fig. 1a: Control, untreated 
clustered microvilli beside 
HCL cells showing 
prominent ruffled 
membrane. 
Fig. 1b: Control HCL cells after 
cultivation without interferon, 
exaggerated ruffles and microvilli. 
one day of 
displaying 
75% and three times 100%) followed by a graded 
series of Freon 113 (TF) in absolute ethanol (25%, 
50%, 75% and three times 100%), for 10 min in each 
solution. Samples fully immersed in Freon 113 were 
picked out one by one with delicate forceps and 
vigorously shaken in the air for about 10s. After 
drying, specimens were mounted on Cambridge 
aluminum stubs using double-sided sticky tape or a 
gluey silver paint. Coverslips with the cell 
monolayers were coated with a thin layer of carbon 
using a sputter coater apparatus (SPI Supplies, 
West Chester, PA). While JEOL JSM-35 SEM was 
used in the preliminary studies, the JEOL 840A, 
equipped with highly-sensitive annular type 
backscattered electron image (BEI) detector, was 
used in recent studies. Attempts to use the GI'GO-
AD technique for preparing gold-labeled cells 
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Fig. 2a: IFN-treated spleen hairy cell showing a 
bud-like formation (arrows) and bubbling membrane 
on the cell body and ruffles (wide arrows). 
Fig. 2b : IFN-treated peripheral blood HCL cell 
displaying a villous bud-like formation (arrows) 
and areas of bubbling membrane (wide arrows). 
resulted in the inability to get BEI of the gold 
particles because of the high background signal 
contributed by the heavy metal solution (Oso4 ). 
Results 
Control PB-HCs were similar to those isolated 
from the spleen, showing variable numbers of 
microvilli, and a wide spectrum of ruffles (Fig. 
la) with minute spikes outlining their uppermost 
profile ("spiked-ruffles"). cultured HCs exhibited 
large ruffles as well as clusters of microvilli, 
and consistent polarity of these surface features 
(Fig. lb). Many of these cultured HCs displayed 
exaggerated, undulating, broa:i-based, "spiked" 
ruffles, whereas clusters of elongated microvilli 
were often encountered. 
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The majority of IFN-treated HCs displayed the 
same surface features characterizing their 
cultured, untreated equivalents. However, distinct 
surface alterations were found in about one-third 
(19 to 36%) of the HCs from the PB and spleen 
specimens in 8 out of the 11 cases treated with 
IFN in-vitro. These changes comprised the 
appearance of a "bubbling" membrane on the cell 
body and/or on the ruffles (Figs. 2a,b), while the 
microvilli became much shorter compared to the 
microvilli of the cultured, untreated cells. The 
majority of these cells also showed a bud-like 
formation at their extremity (Figs. 2a,b) which 
was markedly villous and frequently was the only 
villous part of the cell. The same type of surface 
changes were found in the parallel samples which 
underwent CPD after GA fixation. None of the above 
described surface alterations were encountered in 
control specimens treated with IFN-free NaCl 
solution, nor in cultures that were treated with 
IFN and a neutralizing concentration of an anti-
IFN reagent. 
Some of the above described changes were also 
found in the cultures after 2, or 4 h of 
incubation in the presence of IFN. These cells 
primarily showed bud-like structures whereas 
'bubbling' membranes were rarely seen. However, 
these early changes were found in less than 1S% 
of the HCs. 
Correlative immuno-SEM studies were performed 
to determine the immunological profiles of the 
control untreated cells, and the cultured cells 
with and without IFN treatment. Highly specific 
monoclonal antibodies were used to label the cells 
for B (Leu-14) and T (Leu-4) antigens, and for 
antigens presented by monocytes (Leu--M3, Leu-MS), 
and hairy cells (Leu-MS) • In addition, we used 
anti-HLA-DR and anti-HLA-DQ (Leu-10) reagents to 
assess the expression of class II HLA antigens on 
the treated cells. These immuno-gold labeling 
studies were done on 7 out of the 11 IFN-treated 
cases. All of these cases were positive (higher 
than 60% labeled cells) for Leu-14, Leu-MS, HLA-DR 
and HLA-DQ, and negative (less than S% labeled 
cells) for Leu-4 and Leu-M3. In 2 of these cases 
neither morphological nor immunophenotypical 
changes were noted. The other S cases showed IFN-
induced membrane changes, rut displayed no 
significant alterations in labeling pattern with 
Leu-14 and Leu-MS (Fig. 3). However, all these S 
cases showed a significant increase in the 
labeling pattern for HLA-DQ and HLA-DR (Fig. 4). 
Diverse types of normal and leukemic, 
circulating and cultured leukocytes were used as 
controls in this study. Normal mononuclear cells, 
chronic lymphocytic leukemia and myeloid leukemia 
cells, all did not show any noticeable immuno-
ultrastructural changes when treated with IFN in-
vitro. On the other hand, Daudi (B-lymphoma) 
cultured cells did display a change in their 
villousity. These alterations, which were quite 
different from those exerted by HCs, were 
accompanied by an increase in the expression of 
class II HLA antigens. The above changes were 
abrogated when these cultures were treated with a 
neutralizing concentration of anti-IFN. 
Trypan blue test and careful SEM examinations 
were used to test changes in the viability rates 
of control vs. IFN-treated HCs. In all studied 
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cases, no significant differences in the numbers 
of viable cells were noted, and the viability 
rates were always over 7S% of the total number of 
the cells. 
Discussion 
Interferons are reported to directly 
stimulate cell killing by enhancing the 
cytotoxicity of T-lymphocytes [Sethi and Brandis, 
1978; Zarling et al., 1978], of macrophages 
[Schultz and Chirigos, 1979; Stanwick et al., 
1980], of monocytes [Jett et al., 1980], and of NK 
cells [Welsh, 1981; Herberman et al., 1982] 
against viral-infected cells or tumor cells. The 
mechanism is unknown but it may be related to 
increased synthesis and expression of membrane 
antigens, or may reflect differentiation of the 
immune cells under the influence of IFN. 
Since alpha-, beta-, and gamma-IFN also 
stimulate HLA class I antigen synthesis and the 
expression on the cell surface of antigen-HLA 
complexes, it is possible that this enhances the 
ability of the immune cells to recognize cells 
presenting non-self antigens and destroy them 
[Revel, 1984]. This effect of IFN on recognition 
of non-self antigens on target cells has not been 
demonstrated in-vitro. However, when immune 
deficient patients with low HLA-A or B expression 
are treated with IFN, their cells show an 
increased ability to be recognized by specific 
cytotoxic T cells [Durandy et al . , 1983]. 
Studies have suggested that alpha-, beta-, 
and garrrna-IFNs first bind to cell surface 
receptors and subsequently induce an intracellular 
response [reviewed by Revel, 1984]. After a rapid 
initial binding of IFN, clustering and activation 
of the IFN receptors can take place [Shulman and 
Revel, 1980], and the interaction of IFN with cell 
membranes seems needed to induce the biological 
response. 
In a preliminary study we have shown that 
when HCs are treated in-vitro with alpha-IFN, 
dramatic changes in surface architecture occur in 
up to 32% of the HCs from 3 out of 4 HCL patients 
[Gamliel et al., 1987]. We have also shown that 
the IFN-induced surface alterations were dose and 
time dependent, however, the most dramatic changes 
were encountered in cells treated with 1000 IU IFN 
for 3 days. No significant reduction in the 
viability of cells was noted after IFN treatment, 
suggesting that IFN have had no direct cytotoxic 
effect on in-vitro treated hairy cells. In a 
correlative study on these cases, Samuels et al. 
[1986] have shown that the exposure to IFN also 
caused the induction of specific proteins in the 
treated HCs. The present study demonstrates that 
in 8 out of 11 HCL cases the exposure to IFN 
resulted in specific surface membrane changes, in 
19 to 36% of IFN-treated HCs. The main changes 
were the appearance of small bubbles in the cell 
membrane and the smoothening of otherwise very 
active surface areas which is often accompanied 
with the formation of a markedly villous rud-like 
process at the cell extremity. 
An increase in HLA-A, B, c, and DR antigens 
as well as beta 2 microglobulin, after IFN treatment, was observed on various human cells in-
vitro and in-vivo [Lucero et al., 1982; Basham and 
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Figs. 3a,b: Control hairy cells labeled for Leu-MS 
by colloidal gold. a. SE image of a control cell. 
b. BE image (inverted) of the same cell (the 
black dots represent the marker). 
Merigan, 1983; Rosa et al., 1983]. Burrone and 
Milstein (1982] have described a protein of the 
cell surface of T-leukemic cells (Molt 4) and B-
lymphoblastoid cells (Raji or Daudi), which is 
stron;Jly increased after treatment by alpha-IFN. 
This protein becomes the major surface antigen of 
the IFN-treated cells, but its function is yet 
unknown. On the other hand, human fibroblasts 
treated with IFN showed an increase in the level 
of prostaglandin E [Yaron et al., 1977]. This 
enhanced prostaglandin synthesis was believed to 
be a feerl-back mechanism which protects the cells 
cgainst excessive membrane damage by IFN 
[Fitzpatrick am Strin;Jfella.v, 1980; Gurari-
Rotman, 1982]. 
IFN was also shown to induce a reduction in 
the fluidity of the cell membrane, which is 
closely related to major cytoskeletal 
modifications. Actin containin;J microfilaments 
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Figs. 3c,d: IFN-treated hairy cells labeled for 
Leu-MS by colloidal gold . c. SEI of two cells 
treated with IFN in-vitro (arrows point to a bud-
like formation). d. BE image (inverted) of same 
cells. 
were reported to become more dense and form 
meshworks under the membrane of IFN treaterl HeLa 
or L-929 cells [Tamm et al., 1982; Wang et al., 
1981]. IFN-induced changes in actin microfilaments 
were also reported to impair cell surface receptor 
movements and to inhibit capping of Concanavalin A 
receptors [Pfeffer et al., 1980a,b]. 
The unique IFN-induced morphological changes, 
delineated by SEM in the present and previous 
studies, and the increased expression of class II 
HLA antigens demonstrated in the present study, 
most likely reflect alterations in membranal 
and/or sub-membranal elements of the target cell. 
Membranal reorganization probably plays a major 
role in the response of the cells to IFN, and 
reflects a distinct change in the HCs that might 
initiate their disappearance in HCL patients 
treaterl with IFN in-vivo. 
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Figs. 4a,b: Control hairy cells labeled for HLA-DR 
by colloidal gold. a. SEI of a control cell. b. 
BEI (inverted) of the same cell. 
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Discussion With Reviewers 
M. Revel: This work described very briefly 
observations made after incubating 1 sample of 
spleen cells and 1 sample of peripheral blood 
cells fran hairy cell leukemia patients, with 1000 
U/ml rIFN-alpha for 24 hours. Changes in 
morphology were observed by SEM on 20-30% of the 
cells in these two cases, while no changes seem to 
have been seen in a third case. 
Authors: The aim of this work was to review for 
SEM people the literature on the ability of IFN to 
induce changes in target cells. Beside that goal, 
it brought our results regarding a total number of 
7 cases, of which 3 were new ones. As was stressed 
in the original paper, the changes in morphology 
were seen in 5 out of the 7 studied cases, which 
indicated a unique phenomenon. In this revised 
manuscript we added 4 more cases, and reviewed the 
results from a total of 11 cases treated with IFN 
in -v itro in our lab. These unique alterations were 
seen in 8 out of the 11 cases. 
M. Revel: Leaving aside the fact that the changes 
illustrated only by a couple of micrographs in the 
unique figure, are difficult to see for a non-
expert microscopist, the question is whether these 
20-30% of cells are all the hairy cells in the 
mononuclear cell fraction or whether only 20-30% 
of the hairy cells are modified? The number of 
hairy cells (tartrate-resistant phosphatase 
positive, or stained with specific antibodies) 
should be given for each sample examined. 
Authors: Having in mind the non-expert 
microscopists, we have replaced the original 
photographs and added others that clearly 
demonstrate the differences. Regarding the numbers 
of altered cells, we clearly noted that the 
changes were seen "in 22-31% of IFN-treated HCs", 
which refers to the absolute number of HCs, not to 
the mononuclears. Therefore, the actualnumber of 
hairy cells in each case is not important, but was 
always more than 60% in the PB and more than 80% 
in the spleen, as was noted in the Materials and 
Methods section. 
M. Revel: If only a small proportion of hairy 
cells is affected by IFN, is it possible that 
these changes just reflect the position of the 
cells in the cell-cycle, which could be affected 
by IFN? This seems to me a most critical point. 
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Authors: We do agree that this is a most important 
topic. This whole issue is now under intensive 
study in our laboratory, especially, by the use of 
sync hronized cell samples. We do not agree with 
the use of the word 'just' in this context since 
our aim is to answer the question as to why IFN is 
so effective in some leukemias, and is not 
effective in others. If a proper position in the 
cell cycle enables IFN to react effectively 
through the changes that we described, this might 
be 'just' what we are trying to clarify. 
M. Revel: Furthermore, if changes were not seen in 
1 out of 3 samples is there any relation to 
response to treatment in-vivo? 
Authors: All 11 patients in this study were 
treated with IFN in-vivo. Except in one case, they 
all reacted well to this treatment, as indicated 
by a decrease in the number of malignant cells in 
their blood. The exceptional case also did not 
show morphological changes in-vitro, rut on the 
other hand, the cells from two other cases did not 
display merr.brane alterations under the SEM, but 
reacted well to the drug in-vivo. Thus, further 
studies are necessary to correctly relate the 
response in-vivo to that demonstrated in-vitro by 
ultrastructure. 
M. Revel: Another unanswered question is whether 
such "changes" are seen in other lymphoid cells 
than those of hairy cell leukemia? 
Authors: We are currently studying various types 
of normal and leukemic leukocytes treated with IFN 
in-vitro. So far, none of these cell types did 
show the same changes as did hairy cells. Daudi 
(B-type lymphoma cells) do show some surface 
membrane alterations, mainly, with regard to the 
distribution of surface microvilli, but they do 
not show extensive bubbling of the membrane like 
the IFN-treated hairy cells, nor the same bud-like 
formation. 
Reviewer III: Other questions that are unresolved 
are, for example, whether similar changes can 
occur upon exposure of hairy cell leukemia to 
other biologic response modifiers, such as 
interleukin-2 or BCGF, factors that have produced 
biologic response in-vitro. It is not known 
whether an antibody to interferon alpha will 
abrogate the observed results (which is a final 
test to derive the conclusion that these changes 
are related to interferon). 
Authors: Hairy cells treated with either BCGF or 
interleukin-2 did not show, in our laboratory, 
same surface alterations as did interferon-treated 
hairy cells. On the other hand, when an adequate 
neutralizing concentration of anti-interferon 
antiserum was added to the interferon treated 
cultures, it totally inhibited the induction of 
alterations by interferon. These facts prove that 
the initially described SEM surface changes are 
specific to interferon. 
Reviewer IV: Did you observe bud-like formation 
only in IFN-treated HCs, and did you find the 
microvilli of the treated cells of Fig. 2b much 
shorter than those of untreated cells of Fig. la? 
Authors: The answer to both questions is - yes. 
